Luuk Hilbrands

Luuk Hilbrands

Auto-generated profile, based on publicly available information

Luuk Hilbrands

Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in Nephrology Dialysis Transplantation
Verified
Journal Article
Closed access
LHLuuk B Hilbrands
Luuk B Hilbrands
RDRaphaël Duivenvoorden
Raphaël Duivenvoorden
PVPriya Vart
Priya Vart
CFCasper F M Franssen
Casper F M Franssen
MHMarc H Hemmelder
Marc H Hemmelder
NBNicole Heitink-Ter Braak
Nicole Heitink-Ter Braak
Background. Patients on kidney replacement therapy comprise a vulnerable population and may be at increased risk of death from coronavirus disease 2019 (COVID-19). Currently, only limited data are available on outcomes in this patient population. Methods. We set up the ERACODA (European Renal Association COVID-19 Database) database, which is specifically designed to prospectively collect detailed data on kidney transplant and dialysis patients with COVID-19. For this analysis, patients were included who presented between 1 February and 1 May 2020 and had complete information available on the primary outcome parameter, 28-day mortality. Results. Of the 1073 patients enrolled, 305 (28%) were kidney transplant and 768 (72%) dialysis patients with a mean age of 60 ± 13 and 67 ± 14 years, respectively. The 28-day probability of death was 21.3% [95% confidence interval (95% CI) 14.3–30.2%] in kidney transplant and 25.0% (95% CI 20.2–30.0%) in dialysis patients. Mortality was primarily associated with advanced age in kidney transplant patients, and with age and frailty in dialysis patients. After adjusting for sex, age and frailty, in-hospital mortality did not significantly differ between transplant and dialysis patients [hazard ratio (HR) 0.81, 95% CI 0.59–1.10, P = 0.18]. In the subset of dialysis patients who were a candidate for transplantation (n = 148), 8 patients died within 28 days, as compared with 7 deaths in 23 patients who underwent a kidney transplantation <1 year before presentation (HR adjusted for sex, age and frailty 0.20, 95% CI 0.07–0.56, P < 0.01). Conclusions. The 28-day case-fatality rate is high in patients on kidney replacement therapy with COVID-19 and is primarily driven by the risk factors age and frailty. Furthermore, in the first year after kidney transplantation, patients may be at increased risk of COVID-19-related mortality as compared with dialysis patients on the waiting list for transplantation. This information is important in guiding clinical decision-making, and for informing the public and healthcare authorities on the COVID-19-related mortality risk in kidney transplant and dialysis patients.

19 December 2020 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
ECEra-Edta Council
Era-Edta Council
AOAlberto Ortiz
Alberto Ortiz
Mario CozzolinoMario Cozzolino
Mario Cozzolino
DFDanilo Fliser
Danilo Fliser
DFDenis Fouque
Denis Fouque
PVPriya Vart
Priya Vart
Diabetes, hypertension and cardiovascular disease have been listed as risk factors for severe coronavirus disease 2019 (COVID-19) since the first report of the disease in January 2020. However, this report did not mention chronic kidney disease (CKD) nor did it provide information on the relevance of estimated glomerular filtration rate (eGFR) or albuminuria. As the disease spread across the globe, information on larger populations with greater granularity on risk factors emerged. The recently published OpenSAFELY project analysed factors associated with COVID-19 death in 17 million patients. The picture that arose differs significantly from initial reports. For example, hypertension is not an independent risk factor for COVID-19 death [adjusted hazard ratio (aHR) 0.89], but renal disease very much is. Dialysis (aHR 3.69), organ transplantation (aHR 3.53) and CKD (aHR 2.52 for patients with eGFR <30 mL/min/1.73 m2) represent three of the four comorbidities associated with the highest mortality risk from COVID-19. The risk associated with CKD Stages 4 and 5 is higher than the risk associated with diabetes mellitus (aHR range 1.31–1.95, depending upon glycaemic control) or chronic heart disease (aHR 1.17). In another recent publication, the Global Burden of Disease collaboration identified that worldwide, CKD is the most prevalent risk factor for severe COVID-19. Moreover, the distribution of risk factors for COVID-19 mortality appears to be different in patients with CKD when compared with the general population. The high prevalence of CKD in combination with the elevated risk of mortality from COVID-19 in CKD necessitates urgent action for this group of patients. This article defines essential action points (summarized in Box 1), among which is advocating the inclusion of CKD patients in clinical trials testing the efficacy of drugs and vaccines to prevent severe COVID-19.

1 February 2006 in Blood
Verified
Journal Article
Closed access
JCJeroen J. A. Coenen
Jeroen J. A. Coenen
HKHans J. P. M. Koenen
Hans J. P. M. Koenen
EREsther van Rijssen
Esther van Rijssen
LHLuuk B. Hilbrands
Luuk B. Hilbrands
IJIrma Joosten
Irma Joosten
The immunosuppressive drugs rapamycin and cyclosporin A (CsA) are widely used to prevent allograft rejection. Moreover, they were shown to be instrumental in experimental models of tolerance induction. However, it remains to be elucidated whether these drugs have an effect on the CD4+CD25+ regulatory T-cell (TREG) population, which plays an important role in allograft tolerance. Recently, we reported that alloantigen-driven expansion of human CD4+CD25+ TREGs gives rise to a distinct highly suppressive CD27+TREG subset next to a moderately suppressive CD27-TREG subset. In the current study we found that rapamycin and CsA do not interfere with the suppressive activity of human naturally occurring CD4+CD25+ T cells. However, in contrast to CsA, rapamycin preserved the dominance of the potent CD27+TREG subset over the CD27-TREG subset after alloantigen-driven expansion of CD4+CD25+ TREGs in vitro. Accordingly, CD4+CD25+ TREGs cultured in the presence of rapamycin displayed much stronger suppressive capacity than CD4+CD25+ TREGs cultured in the presence of CsA. In addition, CD4+CD25+ TREG cells cultured in the presence of rapamycin, but not CsA, were able to suppress ongoing alloimmune responses. This differential effect of rapamycin and CsA on the CD27+TREG subset dominance may favor the use of rapamycin in tolerance-inducing strategies.

9 April 2013 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
EKE. G. Kamburova
E. G. Kamburova
HKH. J. P. M. Koenen
H. J. P. M. Koenen
KBK. J. E. Borgman
K. J. E. Borgman
IBI. J. Ten Berge
I. J. Ten Berge
IJI. Joosten
I. Joosten
LHL. B. Hilbrands
L. B. Hilbrands
A single dose of the anti‐CD20 monoclonal antibody rituximab induces a nearly complete B cell depletion in peripheral blood, but not in secondary lymphoid organs. Modulation of this remaining B cell population due to rituximab treatment may contribute to the therapeutic effects of rituximab. To assess the in vivo effects of rituximab we used lymph nodes (LNs) collected during renal transplant surgery in patients who had received rituximab 4 weeks earlier in preparation for an ABO‐incompatible transplantation. Rituximab treatment resulted in a lower percentage of naïve (IgD+CD27−) and a higher percentage of switched memory (IgD−CD27+) B cells. Remarkably, transitional (CD24++CD38++) B cells were virtually lacking in the LNs of rituximab‐treated patients. Moreover, LN‐derived B cells from rituximab‐treated patients produced different amounts of various Ig‐subclasses after anti‐CD40/IL‐21 stimulation ex vivo. Finally, after stimulation of allogeneic T cells with LN‐derived B cells from rituximab‐treated patients, the proliferated T cells showed a decreased production of IL‐17. In conclusion, after treatment with rituximab there remains a B cell population with different functional capacities. Consequently, the effect of rituximab on the immune response will not only be determined by the extent of B cell depletion, but also by the functional properties of the remaining B cells.

13 October 2010 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JJJoannes F.M. Jacobs
Joannes F.M. Jacobs
CPCornelis J.A. Punt
Cornelis J.A. Punt
WLW. Joost Lesterhuis
W. Joost Lesterhuis
RSRoger P.M. Sutmuller
Roger P.M. Sutmuller
HBH. Mary-Lène H. Brouwer
H. Mary-Lène H. Brouwer
GAGosse J. Adema
Gosse J. Adema
Purpose: The success of cancer immunotherapy depends on the balance between effector T cells and suppressive immune regulatory mechanisms within the tumor microenvironment. In this study we investigated whether transient monoclonal antibody–mediated depletion of CD25high regulatory T cells (Treg) is capable of enhancing the immunostimulatory efficacy of dendritic cell vaccines.

26 August 2020 in Nature Reviews Nephrology
Verified
Journal Article
Closed access
PDF file
RGRon T. Gansevoort
Ron T. Gansevoort
LHLuuk B. Hilbrands
Luuk B. Hilbrands